Search Hotels in Sausalito

Find out why investors seeking passive income want shares of this dividend payer in their portfolio.

1 Reason to Buy Bristol Myers Squibb Stock ↗

September 23, 2025

J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study ↗

Topics Intellectual Property

September 17, 2025

Via Stocktwits

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

Topics Artificial Intelligence Intellectual Property

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

The fate of a once-promising cancer treatment now looks uncertain at best.

Why Replimune Stock Plummeted by Almost 40% Today ↗

September 18, 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

September 17, 2025

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

September 16, 2025

Quality yields above 6% from three very different market sectors.

3 Great High-Yield Dividend Stocks to Buy in September ↗

September 16, 2025

BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability ↗

September 15, 2025

Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation.

Via Chartmill

The Specter of Stagflation: A Looming Threat to Global Markets

September 10, 2025

The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high...

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Topics Artificial Intelligence Bonds ETFs

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Via Benzinga

Topics ETFs Government

The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now ↗

September 09, 2025

With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

Topics Intellectual Property

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗

September 08, 2025

Via Benzinga

S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?

September 04, 2025

The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial...

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields ↗

Topics Artificial Intelligence Economy Intellectual Property

September 04, 2025

Via Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

2 Top Dividend Stocks to Buy With Less Than $50 ↗

September 04, 2025

These stocks are cheap in more ways than one.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Topics Intellectual Property

2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off

September 04, 2025

Via StockStory

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles ↗

September 02, 2025

September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains.

Via Benzinga

Topics Stocks

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗

August 30, 2025

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Via Investor's Business Daily

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

August 29, 2025